Putative role of ischemic postconditioning in a rat model of limb ischemia and reperfusion: involvement of hypoxia-inducible factor-1α expression

por Wang, T., Zhou, Y.T., Chen, X.N., Zhu, A.X.
Publicado 2014

Pharmacological inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating T(reg) cells

por Feng, M., Jin, J. Q., Xia, L., Xiao, T., Mei, S., Wang, X., Huang, X., Chen, J., Liu, M., Chen, C., Rafi, S., Zhu, A. X., Feng, Y.-X., Zhu, D.
Publicado 2019

Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study

por Michaelson, M D, Zhu, A X, Ryan, D P, McDermott, D F, Shapiro, G I, Tye, L, Chen, I, Stephenson, P, Patyna, S, Ruiz-Garcia, A, Schwarzberg, A B
Publicado 2013

Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab

por Arnold, D, Fuchs, C S, Tabernero, J, Ohtsu, A, Zhu, A X, Garon, E B, Mackey, J R, Paz-Ares, L, Baron, A D, Okusaka, T, Yoshino, T, Yoon, H H, Das, M, Ferry, D, Zhang, Y, Lin, Y, Binder, P, Sashegyi, A, Chau, I
Publicado 2017

Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer

por Hezel, A F, Noel, M S, Allen, J N, Abrams, T A, Yurgelun, M, Faris, J E, Goyal, L, Clark, J W, Blaszkowsky, L S, Murphy, J E, Zheng, H, Khorana, A A, Connolly, G C, Hyrien, O, Baran, A, Herr, M, Ng, K, Sheehan, S, Harris, D J, Regan, E, Borger, D R, Iafrate, A J, Fuchs, C, Ryan, D P, Zhu, A X
Publicado 2014